Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Islatravir/Lenacapavir - Merck Sharp & Dohme/Gilead Sciences

Next Previous
X
Search
Drug Profile

Islatravir/Lenacapavir - Merck Sharp & Dohme/Gilead Sciences

Alternative Names: Lenacapavir/Islatravir - Merck Sharp & Dohme; MK-8591D

Latest Information Update: 27 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences; Merck Sharp & Dohme
  • Developer Gilead Sciences
  • Class Acetamides; Alkynes; Antiretrovirals; Chlorobenzenes; Fluorinated hydrocarbons; Purine nucleosides; Pyrazoles; Pyridines; Small molecules; Sulfonamides; Sulfones
  • Mechanism of Action Capsid protein inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 19 Oct 2024 Efficacy and adverse events data from a phase II trial in HIV-I infections released by Gilead Sciences
  • 15 Oct 2024 Gilead Sciences plans the phase III ISLEND-1 trial for HIV-1 infections (Treatment-experienced) (PO, Tablet) in October 2024 (NCT06630286)
  • 11 Oct 2024 Gilead Sciences plans the phase III ISLEND-2 trial for HIV-1 infections (Treatment-experienced) (PO, Tablet) in October 2024 (NCT06630299)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top